A potent study showed the overexpression of CPS1 has been linked to both unfavorable therapeutic responses in colorectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy, according to new research (CCRT) [61]. Here, CPS1 is linked to colorectal cancer.